Ovarian cancer is the fourth or fifth most common cause of cancer-related deaths among women worldwide. It is often detected at an advanced stage, which generally results in a poor prognosis and poor survival rate. Early detection is key to improved survival.
CA 125 is, to date, the best known test for ovarian cancer diagnosis. Unfortunately it has a high false positive rate among women with benign gynaecological conditions such as endometriosis. Aproximately 20% of ovarian cancers show no elevated CA125, and levels are not increased in nearly 40-50% of early stage ovarian cancers.
HE4 is a new marker for ovarian cancer. When combined with CA125 it significantly raises the level of sensitivity for the detection of ovarian cancer.
The ROMA classifies patients as being low or high risk for malignant disease using both the CA125 and HE4 results and a woman’s menopausal status.
Please add our blood sampling service to your order.
The following parameters are included:
- ROMA – calculation
Turn around time: 1 day